ClinicalTrials.gg
CompletedNCT04943068Updated Nov 13, 2024

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

A Phase 3 interventional study of Bremelanotide and Placebo in Hypoactive Sexual Desire Disorder, sponsored by Kwang Dong Pharmaceutical co., ltd.. Completed at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-11-13.

Sponsored by Kwang Dong Pharmaceutical co., ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
193
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Study summary

The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).

02

Conditions studied

  • Hypoactive Sexual Desire Disorder

Keywords

  • KD-BMT-301
  • Bremelanotide
03

In context

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

This study's enrollment of 193 is above the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.

Browse Sexual Dysfunctions, Psychological studies →

Lead sponsor

Kwang Dong Pharmaceutical co., ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

[Main Inclusion Criteria]

  • Has met diagnostic criteria for HSDD for at least 6 months
  • Is willing and able to understand and comply with all study requirements
  • Has a normal pelvic examination at screening

[Main Exclusion Criteria]

  • Subjects should be generally healthy premenopausal females with no psychological, gynecological or urological conditions which might contribute to the sexual dysfunction, compromise study participation, or confound interpretation of the study results
  • Not currently under treatment for the sexual dysfunction and willing to forego other treatments through the course of the clinical trial
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    Bremelanotide

    Bremelanotide (BMT) subcutaneously (SC) via auto-injector for 8-weeks double-Blind period

    Drug: Bremelanotide

  • Placebo comparator
    Placebo

    Placebo subcutaneously (SC) via auto-injector for 4-weeks single-Blind period and for 8-weeks double-Blind period

    Drug: Placebo

Interventions

  • Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.

  • DrugPlacebo

    Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.

06

What researchers measure

Primary outcomes

  1. Change from baseline to End of Study in the desire domain from the FSFI

    Time frame: Baseline up to End of Study(8weeks)

Secondary outcomes

  1. Change from baseline to End of Study in FSDS-DAO (Item 13)

    Time frame: Baseline up to End of Study(8weeks)

  2. Change from Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration

    Time frame: Baseline up to End of Study(8weeks)

  3. Change from Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R

    Time frame: Baseline up to End of Study(8weeks)

  4. Change from Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R

    Time frame: Baseline up to End of Study(8weeks)

  5. Change from Baseline to End of Study in the FSDS-DAO Total Score

    Time frame: Baseline up to End of Study(8weeks)

  6. Change from Baseline to End of study in the total FSFI score based on the 19 questions

    The FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.

    Time frame: Baseline up to End of Study(8weeks)

  7. Change in mean Level of Sexual Arousal from FSEP-R Q6

    Time frame: Baseline up to End of Study(8weeks)

  8. Change in mean Satisfaction with Sexual Arousal from FSEP-R Q7.

    Time frame: Baseline up to End of Study(8weeks)

  9. Change from Baseline to End of study in the scored time spent being concerned by difficulty with sexual arousal as measured by the FSDS-DAO Q14.

    Time frame: Baseline up to End of Study(8weeks)

  10. Change from Baseline to End of study in the arousal domain from the FSFI Q3 through Q6.

    Time frame: Baseline up to End of Study(8weeks)

  11. Change from Baseline to End of study in the total number of SSEs.

    Time frame: Baseline up to End of Study(8weeks)

  12. Change from baseline in the desire domain from the FSFI Q1 and Q2 using all available double-blind data (visit 4, 5)

    Time frame: Baseline up to End of Study(8weeks)

  13. Change from baseline in the score for feeling bothered by low sexual desire as measured by the FSDS -DAO Q13 using all available double-blind data(visit 4, 5)

    Time frame: Baseline up to End of Study(8weeks)

  14. Change from baseline in the number of SSEs associated with study drug using the entire 8 weeks of the double-blind phase.

    Time frame: Baseline up to End of Study(8weeks)

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in May 2023, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2021
First posted
Jun 29, 2021
StartActual
May 10, 2021
Primary completionActual
May 16, 2023
CompletionActual
May 16, 2023
Last update
Nov 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04943068
Lead sponsor
Kwang Dong Pharmaceutical co., ltd.
Responsible party
Sponsor
First posted
Jun 29, 2021
Start date
May 10, 2021
Primary completion
May 16, 2023
Completion
May 16, 2023
Last update
Nov 13, 2024

Study contacts

Soo Woong Kim, Dr
principal investigator · Seoul National University Hospital
Tak Kim, Dr
principal investigator · Korea University Anam Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bremelanotide

Start the discussion